Recent guidelines recommend testing the tumors of all patients with CRC with either IHC or for MSI to identify potential cases of LS; moreover, all patients meeting AC or BL should be offered germline genetic testing for mutations in MLH1, MSH2, MSH6 and PMS2 [13]. Here, MLH1 is linked to colorectal carcinoma.